Primary Mediastinal Large B Cell Lymphoma Clinical Trials

62 clinical trials for Primary Mediastinal Large B Cell Lymphoma across international registries, including 25 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma — RECRUITING · PHASE2
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients — RECRUITING · PHASE1
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Long-term Study to Evaluate Safety and Persistence of GF-CART01 — RECRUITING
• Bio-CAR-T BS Study — RECRUITING
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients — RECRUITING · PHASE1
• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Pembro Plus CAR T-cell Therapy in R/R in PMBCL — RECRUITING · PHASE2
• Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma — RECRUITING · PHASE1
• CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies — RECRUITING · PHASE1
• Study of SGR-1505 in Mature B-Cell Neoplasms — RECRUITING · PHASE1
• Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors — RECRUITING · NA
• Emapalumab Prevention of CAR-T Cell Associated Toxicities — RECRUITING · PHASE2
• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment — RECRUITING
• CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas — RECRUITING · PHASE1
• Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy — RECRUITING
• Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma — RECRUITING · PHASE1
• Immunotherapy in Lymphoma — RECRUITING
• Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy — RECRUITING · PHASE2
• Italian Observational Study on CAR-T Therapy for Lymphoma — RECRUITING
• Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) — RECRUITING · NA
• Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy — COMPLETED · PHASE1
• Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) — ACTIVE_NOT_RECRUITING · PHASE1
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients — NOT_YET_RECRUITING · PHASE1
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) — NOT_YET_RECRUITING · PHASE1
• ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies — COMPLETED · PHASE1
• Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study — COMPLETED
• P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T — COMPLETED · PHASE1
• Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma — COMPLETED · PHASE1
• Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation — COMPLETED · PHASE2
• Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) — COMPLETED · PHASE2
• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma — COMPLETED
• Primary Mediastinal Large B-cell Lymphoma With CNS Involvement — ACTIVE_NOT_RECRUITING
• Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma — COMPLETED · PHASE2
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma — OTHER · PHASE2
• First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas — TERMINATED · PHASE1
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies — COMPLETED · PHASE1
• A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment — OTHER · PHASE2
• Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL — COMPLETED · PHASE1
• LITT and Pembrolizumab in Recurrent Brain Metastasis — TERMINATED · PHASE1
• Expanded Access Program for Epcoritamab — OTHER

Refine this search